GlassScriptPhysician profile
Barbara B Cortez
NPI 1114994068
$20,507.50
in general payments reported to CMS, 2019-2025
33 companies · $4,733 in 2025
The $4,733 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $1,040 · 2021: $1,953 · 2022: $3,314 · 2023: $3,653 · 2024: $4,548 · 2025: $4,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,522.47 |
| Education | $411.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,368.37 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,521.08 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $1,302.45 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,267.92 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,201.05 | 2022-2025 | Opzelura |
| Pfizer INC. | $1,125.36 | 2019-2025 | |
| Ucb, INC. | $998.33 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $994.63 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $900.59 | 2023-2025 | Zoryve |
| Genzyme Corporation | $812.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $725.72 | 2019-2025 | |
| Dermavant Sciences, INC. | $704.40 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $699.97 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $551.61 | 2019-2024 | Cabtreo, Arazlo, Siliq |
| Leo Pharma INC. | $501.69 | 2019-2025 | Adbry, Anzupgo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $432.95 | 2020-2025 | Seysara, Klisyri |
| Galderma Laboratories, L.P. | $394.56 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Biofrontera INC. | $371.73 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $339.65 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $252.76 | 2019-2025 | |
| Epi Health, LLC | $194.74 | 2021-2022 | |
| Amgen INC. | $188.97 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $129.55 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $128.01 | 2022 | |
| Organon LLC | $98.05 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.68 | 2022-2023 | Cyltezo |
| Journey Medical Corporation | $43.13 | 2022-2023 | |
| Medimetriks Pharmaceuticals, INC. | $42.73 | 2023 | Neo-Synalar |
| Prugen, INC. Pharmaceuticals | $41.63 | 2019-2020 | |
| Dermira, INC. | $38.86 | 2021 | |
| Krystal Biotech INC | $24.69 | 2023 | Vyjuvek |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Nabriva Therapeutics, Plc | $17.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Cortez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.